Janette Reader

Dr. Janette Reader


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2017 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
TPTanya Paquet
Tanya Paquet
CMClaire Le Manach
Claire Le Manach
DCDiego González Cabrera
Diego González Cabrera
YYYassir Younis
Yassir Younis
PHPhilipp P. Henrich
Philipp P. Henrich
KCKelly Chibale
Kelly Chibale
MMV390048, a member of a new class of inhibitors of the Plasmodium phosphatidylinositol 4-kinase, shows potential for both treatment and prophylaxis.

22 May 2015 in Malaria Journal
Verified
Journal Article
Open access
PDF file
JRJanette Reader
Janette Reader
MBMariëtte Botha
Mariëtte Botha
ATAnjo Theron
Anjo Theron
SLSonja B Lauterbach
Sonja B Lauterbach
CRClaire Rossouw
Claire Rossouw
LBLyn-Marie Birkholtz
Lyn-Marie Birkholtz
The discovery of malaria transmission-blocking compounds is seen as key to malaria elimination strategies and gametocyte-screening platforms are critical filters to identify active molecules. However, unlike asexual parasite assays measuring parasite proliferation, greater variability in end-point readout exists between different gametocytocidal assays. This is compounded by difficulties in routinely producing viable, functional and stage-specific gametocyte populations. Here, a parallel evaluation of four assay platforms on the same gametocyte populations was performed for the first time. This allowed the direct comparison of the ability of different assay platforms to detect compounds with gametocytocidal activity and revealed caveats in some assay readouts that interrogate different parasite biological functions. Gametocytogenesis from Plasmodium falciparum (NF54) was optimized with a robust and standardized protocol. ATP, pLDH, luciferase reporter and PrestoBlue® assays were compared in context of a set of 10 reference compounds. The assays were performed in parallel on the same gametocyte preparation (except for luciferase reporter lines) using the same drug preparations (48 h). The remaining parameters for each assay were all comparable. A highly robust method for generating viable and functional gametocytes was developed and comprehensively validated resulting in an average gametocytaemia of 4 %. Subsequent parallel assays for gametocytocidal activity indicated that different assay platforms were not able to screen compounds with variant chemical scaffolds similarly. Luciferase reporter assays revealed that synchronized stage-specific gametocyte production is essential for drug discovery, as differential susceptibility in various gametocyte developmental populations is evident. With this study, the key parameters for assays aiming at testing the gametocytocidal activity of potential transmission blocking molecules against Plasmodium gametocytes were accurately dissected. This first and uniquely comparative study emphasizes differential effects seen with the use of different assay platforms interrogating variant biological systems. Whilst this data is informative from a biological perspective and may provide indications of the drug mode of action, it does highlight the care that must be taken when screening broad-diversity chemotypes with a single assay platform against gametocytes for which the biology is not clearly understood.

26 October 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CMClaire Le Manach
Claire Le Manach
ANAloysius T. Nchinda
Aloysius T. Nchinda
TPTanya Paquet
Tanya Paquet
DCDiego Gonzàlez Cabrera
Diego Gonzàlez Cabrera
YYYassir Younis
Yassir Younis
KCKelly Chibale
Kelly Chibale

19 October 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
LALauren B. Arendse
Lauren B. Arendse
JMJames M. Murithi
James M. Murithi
TQTarrick Qahash
Tarrick Qahash
Charisse Flerida PasajeCharisse Flerida Pasaje
Charisse Flerida Pasaje
LGLuiz C. Godoy
Luiz C. Godoy
KCKelly Chibale
Kelly Chibale
Compounds acting on multiple targets are critical to combating antimalarial drug resistance. Here, we report that the human “mammalian target of rapamycin” (mTOR) inhibitor sapanisertib has potent prophylactic liver stage activity, in vitro and in vivo asexual blood stage (ABS) activity, and transmission-blocking activity against the protozoan parasite Plasmodium spp. Chemoproteomics studies revealed multiple potential Plasmodium kinase targets, and potent inhibition of Plasmodium phosphatidylinositol 4-kinase type III beta (PI4Kβ) and cyclic guanosine monophosphate–dependent protein kinase (PKG) was confirmed in vitro. Conditional knockdown of PI4Kβ in ABS cultures modulated parasite sensitivity to sapanisertib, and laboratory-generated P. falciparum sapanisertib resistance was mediated by mutations in PI4Kβ. Parasite metabolomic perturbation profiles associated with sapanisertib and other known PI4Kβ and/or PKG inhibitors revealed similarities and differences between chemotypes, potentially caused by sapanisertib targeting multiple parasite kinases. The multistage activity of sapanisertib and its in vivo antimalarial efficacy, coupled with potent inhibition of at least two promising drug targets, provides an opportunity to reposition this pyrazolopyrimidine for malaria.

1 September 2018 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
CBChristel Brunschwig
Christel Brunschwig
NLNina Lawrence
Nina Lawrence
DTDale Taylor
Dale Taylor
EAEfrem Abay
Efrem Abay
MNMathew Njoroge
Mathew Njoroge
KCKelly Chibale
Kelly Chibale
The 2-aminopyridine MMV048 was the first drug candidate inhibiting Plasmodium phosphatidylinositol 4-kinase (PI4K), a novel drug target for malaria, to enter clinical development. In an effort to identify the next generation of PI4K inhibitors, the series was optimized to improve properties such as solubility and antiplasmodial potency across the parasite lifecycle, leading to the 2-aminopyrazine UCT943. The compound displayed higher asexual blood stage, transmission-blocking, and liver stage activity than MMV048 and was more potent against resistant P. falciparum and P. vivax clinical isolates. Excellent in vitro antiplasmodial activity translated into high efficacy in P. berghei and humanized P. falciparum NOD-scid IL-2Rγnull mouse models. The high passive permeability and high aqueous solubility of UCT943, combined with low to moderate in vitro intrinsic clearance, resulted in sustained exposure and high bioavailability in preclinical species. In addition, the predicted human dose for a curative single administration using monkey and dog pharmacokinetics was low, ranging from 50 to 80 mg. As a next generation Plasmodium PI4K inhibitor, the combined preclinical data suggest that UCT943 has the potential to form part of a single-exposure radical cure and prophylaxis (SERCaP) to treat, prevent and block the transmission of malaria.

7 February 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KSKawaljit Singh
Kawaljit Singh
JOJohn Okombo
John Okombo
CBChristel Brunschwig
Christel Brunschwig
FNFerdinand Ndubi
Ferdinand Ndubi
LBLinley Barnard
Linley Barnard
KCKelly Chibale
Kelly Chibale